Disease indication - Cancer, specifically:
-highly mutated cancers, including the ~20% of cancer with BAF complex mutations
-combination therapy with ATR inhibitors
Researchers in Prof. Gerald Crabtree's laboratory have identified the pathological mechanism for synovial sarcoma (SS) that could be used to develop targeted therapeutics. This approach aims to reverse the effects of the SS18-SSX fusion protein (the hallmark of human SS).
Researchers in Prof. Gerald Crabtree's laboratory have developed a method for identifying cancer patients that are likely to benefit from treatment with topoisomerase IIa (TOP2A) inhibitors.